India Poised to Lead Global Genomics Revolution: Report

India is building capabilities in these fields through initiatives such as the Biopharma Shakti scheme and the Genome India Project mapping 10,000 genomes across 99 ethnic groups, the report said.

bolt Latest News Updates for You

Sensex, Nifty Open Lower as IT Stocks Slip; Crude at $114

NEW

Gold, Silver Rebound on MCX; Gold Still Near 3-Month Low

Sensex, Nifty Open Lower as IT Stocks Drag Markets

The firm noted India’s domestic genomics market is growing at over 16 per cent annually and is actively building toward this moment.

Globally, artificial intelligence is compressing drug discovery timelines from a decade to under 18 months and clinical genomic data and machine learning are producing commercial revenue that validates faster development.

Also Read

Gold, Silver Rebound on MCX; Gold Still Near 3-Month Low Markets

Across the genomics sector, companies are now using clinical genomic data to accelerate target identification at a scale no conventional research organisation could match.

Some platforms are running over a million biological experiments weekly using machine learning. 

Biopharma M&A reached $106 billion across 201 deals in just the first half of 2026, on pace for the strongest full year since pre-pandemic.  

In the first half of 2026, biotech IPOs raised more capital than the entire sector managed across all of 2025 a year when only 11 companies went public globally. Venture capital deployed into biotech hit $38 billion in 2025, up 28 per cent year-on-year.